Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Organization of the Anterior Limb of the Internal Capsule in the Rat.

Coizet V, Heilbronner SR, Carcenac C, Mailly P, Lehman JF, Savasta M, David O, Deniau JM, Groenewegen HJ, Haber SN.

J Neurosci. 2017 Mar 8;37(10):2539-2554. doi: 10.1523/JNEUROSCI.3304-16.2017. Epub 2017 Feb 3.

PMID:
28159909
2.

Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.

Favier M, Carcenac C, Drui G, Vachez Y, Boulet S, Savasta M, Carnicella S.

Sci Rep. 2017 Jan 30;7:41589. doi: 10.1038/srep41589.

3.

What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?

Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M, Boulet S, Carnicella S.

Transl Psychiatry. 2016 Mar 8;6:e753. doi: 10.1038/tp.2016.17. Review.

4.

Chronic Intermittent Hypoxia Induces Chronic Low-Grade Neuroinflammation in the Dorsal Hippocampus of Mice.

Sapin E, Peyron C, Roche F, Gay N, Carcenac C, Savasta M, Levy P, Dematteis M.

Sleep. 2015 Oct 1;38(10):1537-46. doi: 10.5665/sleep.5042.

5.

Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats.

Carcenac C, Favier M, Vachez Y, Lacombe E, Carnicella S, Savasta M, Boulet S.

Mov Disord. 2015 Nov;30(13):1739-49. doi: 10.1002/mds.26146. Epub 2015 Jan 14.

PMID:
25588931
6.

Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.

Bosson A, Boisseau S, Buisson A, Savasta M, Albrieux M.

Glia. 2015 Apr;63(4):673-83. doi: 10.1002/glia.22777. Epub 2014 Dec 15.

PMID:
25511180
7.

Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.

Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T, Savasta M.

Transl Psychiatry. 2014 Jun 17;4:e401. doi: 10.1038/tp.2014.43.

8.

Pramipexole reverses Parkinson's disease-related motivational deficits in rats.

Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S.

Mov Disord. 2014 Jun;29(7):912-20. doi: 10.1002/mds.25837. Epub 2014 Feb 11.

PMID:
24515412
9.

High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson's disease.

Favier M, Carcenac C, Drui G, Boulet S, El Mestikawy S, Savasta M.

BMC Neurosci. 2013 Dec 5;14:152. doi: 10.1186/1471-2202-14-152.

10.

Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.

Rolland M, Carcenac C, Overton PG, Savasta M, Coizet V.

Neuroscience. 2013 Nov 12;252:277-88. doi: 10.1016/j.neuroscience.2013.07.047. Epub 2013 Jul 31.

PMID:
23916713
11.

Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.

Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S, Savasta M.

Mol Psychiatry. 2014 Mar;19(3):358-67. doi: 10.1038/mp.2013.3. Epub 2013 Feb 12.

12.

IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.

Aron Badin R, Spinnewyn B, Gaillard MC, Jan C, Malgorn C, Van Camp N, Dollé F, Guillermier M, Boulet S, Bertrand A, Savasta M, Auguet M, Brouillet E, Chabrier PE, Hantraye P.

PLoS One. 2013;8(1):e52680. doi: 10.1371/journal.pone.0052680. Epub 2013 Jan 3.

13.

Mitochondrial permeability transition pore inhibitors prevent ethanol-induced neuronal death in mice.

Lamarche F, Carcenac C, Gonthier B, Cottet-Rousselle C, Chauvin C, Barret L, Leverve X, Savasta M, Fontaine E.

Chem Res Toxicol. 2013 Jan 18;26(1):78-88. doi: 10.1021/tx300395w. Epub 2013 Jan 7.

PMID:
23268549
14.

Does MPTP intoxication in mice induce metabolite changes in the nucleus accumbens? A ¹H nuclear MRS study.

Chassain C, Bielicki G, Carcenac C, Ronsin AC, Renou JP, Savasta M, Durif F.

NMR Biomed. 2013 Mar;26(3):336-47. doi: 10.1002/nbm.2853. Epub 2012 Oct 12.

PMID:
23059905
15.

Subthalamic nucleus electrical stimulation modulates calcium activity of nigral astrocytes.

Barat E, Boisseau S, Bouyssières C, Appaix F, Savasta M, Albrieux M.

PLoS One. 2012;7(7):e41793. doi: 10.1371/journal.pone.0041793. Epub 2012 Jul 27.

16.

Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.

Quintana A, Sgambato-Faure V, Savasta M.

Neurobiol Dis. 2012 Dec;48(3):379-90. doi: 10.1016/j.nbd.2012.06.009. Epub 2012 Jun 30.

17.

Incidence of neoplastic disease in cardiac allograft recipients.

Savasta M, Lentini S.

Rev Cardiovasc Med. 2011;12(4):219-26. doi: 10.3909/ricm0582. Review.

PMID:
22249512
18.

Immunology insights into cardiac allograft rejection.

Savasta M, Lentini S.

Rev Cardiovasc Med. 2011;12(2):e68-76. Review.

PMID:
21796085
19.

Incidence of neoplastic disease following lung transplantation: a 17-year single-center experience.

Pellegrini C, Nicolardi S, Savasta M, Totaro P, Meloni F, Ippoliti G, Oggionni T, Raffa G, D'Armini AM, Viganò M.

Transplant Proc. 2011 May;43(4):1156-8. doi: 10.1016/j.transproceed.2011.02.041.

PMID:
21620076
20.

Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G, Bezard E.

PLoS One. 2010 Aug 23;5(8):e12322. doi: 10.1371/journal.pone.0012322.

Supplemental Content

Loading ...
Support Center